Fundraising FoxNgm Biopharmaceuticals
AcquiredSouth San Francisco, US · Delaware corporation · 3 known investors
Find your way into Ngm Biopharmaceuticals
Sign up to see every warm intro you have to Ngm Biopharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ngm Biopharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by The Column Group February 2024 · $135M ($1.55 per share cash, ~$135 million total equity value) · source ↗
NGM Biopharmaceuticals is a clinical-stage biotech developing biologic drugs for cardio-metabolic, liver, oncology, and pregnancy-related conditions based on proprietary disease pathway research.
Founders & leadership
Board
Investors · 3
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: Prospect Venture Partners's portfolio page · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$126.7M disclosed across 2 rounds · 2014–2015
▶$106MraisedMar 2015 · 1 investors · BiotechnologyRule 506(b)
- Mark LeschlyDirector
- Peter SvennilsonDirector
- David SchnellDirector
- David V. GoeddelDirector
- Jin-Long ChenExecutive Officer, Director
- William J. RieflinExecutive Officer, Director
- McHenry T. Tichenor, Jr.Director
- Offering amount
- $106M
- Amount sold
- $106M
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.7MraisedFeb 2015 · 20 investors · BiotechnologyRule 506(b)
- McHenry T. Tichenor, Jr.Director
- William J. RieflinExecutive Officer, Director
- Peter SvennilsonDirector
- Jin-Long ChenExecutive Officer, Director
- Mark LeschlyDirector
- David V. GoeddelDirector
- David SchnellDirector
- Offering amount
- $60M
- Amount sold
- $20.7M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Ngm Biopharmaceuticals do?
- NGM Biopharmaceuticals is a clinical-stage biotech developing biologic drugs for cardio-metabolic, liver, oncology, and pregnancy-related conditions based on proprietary disease pathway research.
- Who founded Ngm Biopharmaceuticals?
- Ngm Biopharmaceuticals was founded by Jin-Long Chen.
- Who are Ngm Biopharmaceuticals's investors?
- Ngm Biopharmaceuticals's investors include Foresite Capital, Prospect Venture Partners, The Column Group.
- How much funding has Ngm Biopharmaceuticals raised?
- Ngm Biopharmaceuticals has disclosed $126.7M raised across 2 rounds.
- Where is Ngm Biopharmaceuticals headquartered?
- Ngm Biopharmaceuticals is headquartered in South San Francisco, US.